{"id":34030,"date":"2026-05-06T10:26:07","date_gmt":"2026-05-06T10:26:07","guid":{"rendered":"https:\/\/www.europesays.com\/canada\/34030\/"},"modified":"2026-05-06T10:26:07","modified_gmt":"2026-05-06T10:26:07","slug":"flora-fertility-plots-canadian-expansion-after-successful-u-s-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/canada\/34030\/","title":{"rendered":"Flora Fertility plots Canadian expansion after successful U.S. trial"},"content":{"rendered":"

Flora Fertility, a dual-headquartered Canadian and U.S. startup that provides insurance for fertility treatments, plans to launch its services in Canada by early next year, after first doing so south of the border.\u00a0<\/p>\n

Co-CEO and co-founder Laura J. McDonald told The Logic that launching a new health insurance service in Canada is more complex than doing so in the U.S., where the firm started operating in a closed beta in September 2025.<\/p>\n

Talking Points<\/p>\n

Canada and U.S.-based Flora Fertility, which provides insurance for fertility treatments, has been operating in the U.S. since September 2025, until recently as a closed beta
\nOn the heels of a US$5-million seed round, the startup is preparing to launch in Canada where regulations make a quick, national rollout trickier<\/p>\n

\u201cThere are just different challenges no matter what markets you take on,\u201d McDonald said. \u201cAs a startup, we need to prioritize one market first and then be in a position to expand.\u201d<\/p>\n

Founded in 2023, Flora provides coverage for fertility treatments that are often not fully covered by private or public insurance in Canada and the U.S. It charges a monthly premium for up to US$50,000 lifetime coverage for fertility treatment.<\/p>\n

\t\t\t\t\tRelated Articles<\/p>\n

\t
\n\t\"\"\t<\/a><\/p>\n

A single round of in vitro fertilization in Canada can cost up to $20,000, according to Fertility Matters Canada, a reproductive health organization. Olive Fertility, a B.C.-based clinic, estimates a round at between $20,700 and $24,700, depending on medication costs, and not including genetic testing of embryos or eventual transfers.<\/p>\n

Despite high costs, many people are turning to fertility treatments. In Canada, an estimated one in six adults struggles with infertility. The demand for such services and the high cost caught the attention of Flora\u2019s co-founders. Most people don\u2019t even have $10,000 in emergency savings, said McDonald, who watched a family member undergo fertility treatment and wanted to find a way to help people ease the financial burden.<\/p>\n

Flora raised $1.5 million in pre-seed funding in 2024 and recently announced<\/a> a US$5-million seed round, which included participation from BDC. To date, the firm has raised about $9 million, according to its co-founders.\u00a0<\/p>\n

It is always difficult to raise funds as a female founder for a female-focused business, said co-founder and co-CEO Christy Lane. Despite this, Flora received a lot of interest from investors who want to capitalize<\/a> on the opportunity they see in fertility startups, said McDonald.<\/p>\n

Flora chose to launch in the U.S., as many Canadian healthtech startups do, for several reasons. For starters, the market size is about 10 times bigger than in Canada, said McDonald, and investors want to see that kind of scale when committing funds.\u00a0<\/p>\n

The reinsurers that Flora works with also need to know \u201cthat the town is big enough and the market is big enough for them\u201d to want to divert dollars, McDonald said.<\/p>\n

In the U.S., Flora chose a structure that allowed it to launch across all 50 states at the same time rather than jump through different hoops for each state. In Canada, Lane claimed, that isn\u2019t possible.<\/p>\n

Flora recently left its U.S. beta period behind, and is gearing up for a launch in Canada. It has hired its first full-time staff beyond its two co-founders, including a chief financial officer and chief operating officer.\u00a0<\/p>\n

Its launch in Canada is likely to happen province by province due to the patchwork of regulations, said Lane. She reckons Flora will most likely start operating in a jurisdiction where there is no public funding available for fertility treatments, likely Alberta.\u00a0<\/p>\n

All provinces except Alberta offer some funding, with Yukon the only territory to offer financial help. Public fertility funding\u2014often in the form of a tax credit or grant\u2014has become somewhat more common in recent years, with more provinces and territories offering help.<\/p>\n

Flora doesn\u2019t believe the uptick in public funding availability will impact its business model. What\u2019s available is limited, said Lane. In Ontario, for example, funding covers one IVF cycle but no medications, which can cost upwards of $5,000. \u201cEven if there were two cycles covered, that\u2019s likely, in most cases, not going to be enough for most women and families,\u201d she said.<\/p>\n","protected":false},"excerpt":{"rendered":"Flora Fertility, a dual-headquartered Canadian and U.S. startup that provides insurance for fertility treatments, plans to launch its…\n","protected":false},"author":2,"featured_media":34031,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[525,17,2128,7875],"class_list":{"0":"post-34030","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-canada","8":"tag-business","9":"tag-canada","10":"tag-health","11":"tag-startups"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts\/34030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/comments?post=34030"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts\/34030\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/media\/34031"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/media?parent=34030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/categories?post=34030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/tags?post=34030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}